[1] Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP[J]. Neurology, 2018, 91:1051-1060. [2] Uncini A, Susuki K, Yuki N. Nodo-paranodopathy:beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies[J]. Clin Neurophysiol, 2013, 124:1928-1934. [3] Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Léger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN; European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy:report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society:first revision[J]. Eur J Neurol, 2010, 17:356-363. [4] Zhang X, Zheng P, Devaux JJ, Wang Y, Liu C, Li J, Guo S, Song Y, Wang Q, Feng X, Wang Y. Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China[J]. J Neuroimmunol, 2019, 337:577074. [5] Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, Kuwahara M, Suzuki H, Kusunoki S, Fujimoto Y, Ikezoe K, Kishida H, Tanaka F, Matsushita T, Murai H, Kira J. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy[J]. Ann Clin and Transl Neurol, 2015, 2:960-971. [6] Delmont E, Brodovitch A, Kouton L, Allou T, Beltran S, Brisset M, Camdessanché JP, Cauquil C, Cirion J, Dubard T, Echaniz-Laguna A, Grapperon AM, Jauffret J, Juntas-Morales R, Kremer LD, Kuntzer T, Labeyrie C, Lanfranco L, Maisonobe T, Mavroudakis N, Mecharles-Darrigol S, Nicolas G, Noury JB, Perie M, Rajabally YA, Remiche G, Rouaud V, Tard C, SalortCampana E, Verschueren A, Viala K, Wang A, Attarian S, Boucraut J. Antibodies against the node of Ranvier:a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera[J]. J Neurol, 2020, 267:3664-3672. [7] Garg N, Park SB, Yiannikas C, Vucic S, Howells J, Noto YI, Mathey EK, Pollard JD, Kiernan MC. Neurofascin-155 IgG4 neuropathy:pathophysiological insights, spectrum of clinical severity and response to treatment[J]. Muscle Nerve, 2018, 57:848-851. [8] Fujita A, Ogata H, Yamasaki R, Matsushita T, Kira JI. Parallel fluctuation of anti-neurofascin 155 antibody levels with clinicoelectrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy[J]. J Neurol Sci, 2018, 384:107-112. [9] Sun C, Lin J, Qiao K, Jiao YQ, Liu BY, Liu XN, Chen XJ, Zhao CB, Lu JH. Characteristics in chronic inflammatory demyelinating polyradiculoneuropathy associated with anti-neurofascin 155 IgG4 antibodies[J]. Zhongguo Lin Chuang Shen Jing Ke Xue, 2019, 27:411-418.[孙翀,林洁,乔凯,焦宇琼,刘炳佑,刘小妮,陈向军,赵重波,卢家红.抗神经束蛋白155-IgG4抗体阳性的慢性炎性脱髓鞘性多发性神经根神经病临床特点分析[J].中国临床神经科学, 2019, 27:411-418.] [10] Tang L, Huang Q, Qin Z, Tang X. Distinguish CIDP with autoantibody from that without autoantibody:pathogenesis, histopathology, and clinical features[J]. J Neurol, 2021, 268:2757-2768. [11] Ogata H, Zhang X, Inamizu S, Yamashita KI, Yamasaki R, Matsushita T, Isobe N, Hiwatashi A, Tobimatsu S, Kira JI. Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody[J]. Ann Clin Transl Neurol, 2020, 7:2297-2309. [12] Kawamura N, Yamasaki R, Yonekawa T, Matsushita T, Kusunoki S, Nagayama S, Fukuda Y, Ogata H, Matsuse D, Murai H, Kira J. Anti-neurofascin antibody in patients with combined central and peripheral demyelination[J]. Neurology, 2013, 81:714-722. [13] Lv H, Meng L, Yu M, Zhang W, Wang Z, Yuan Y. Dissociation of axo-glial junction in anti-neurofascin 155 chronic inflammatory demyelinating polyneuropathy[J]. Clin Neuropathol, 2021, 40:87-92. [14] Briani C, Cocito D, Campagnolo M, Doneddu PE, Nobile-Orazio E. Update on therapy of chronic immune-mediated neuropathies[J]. Neurol Sci, 2021.[Epub ahead of print] [15] Muley SA, Jacobsen B, Parry G, Usman U, Ortega E, Walk D, Allen J, Pasnoor M, Varon M, Dimachkie MM. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy[J]. Muscle Nerve, 2020, 61:575-579. [16] Jiao L, Xiang Y, Li S, Zhang F, Ruan X, Guo S. Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155[J]. J Neuroimmunol, 2020, 345:577280. [17] Godil J, Barrett MJ, Ensrud E, Chahin N, Karam C. Refractory CIDP:clinical characteristics, antibodies and response to alternative treatment[J]. J Neurol Sci, 2020, 418:117098. [18] Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Seró-Ballesteros L, Carvajal A, Ortiz N, Gallardo E, Illa I. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2:e149. [19] Kuwahara M, Suzuki H, Oka N, Ogata H, Yanagimoto S, Sadakane S, Fukumoto Y, Yamana M, Yuhara Y, Yoshikawa K, Morikawa M, Kawai S, Okazaki M, Tsujimoto T, Kira JI, Kusunoki S. Electron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody[J].Muscle Nerve, 2018, 57:498-502. [20] Appeltshauser L, Brunder AM, Heinius A, K?rtvélyessy P, Wandinger KP, Junker R, Villmann C, Sommer C, Leypoldt F, Doppler K. Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7:e817. |